Detalhe da pesquisa
1.
COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study.
J Am Acad Dermatol
; 84(5): 1412-1415, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33581187
2.
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.
Future Oncol
; 11(3): 421-9, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25675123
3.
Access to melanoma drugs in Spain: a cross-sectional survey.
Clin Transl Oncol
; 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38750345
4.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol
; 13(3): 239-46, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22285168
5.
SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry.
Clin Transl Oncol
; 25(3): 768-775, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36566266
6.
Multiplex Analysis of CircRNAs from Plasma Extracellular Vesicle-Enriched Samples for the Detection of Early-Stage Non-Small Cell Lung Cancer.
Pharmaceutics
; 14(10)2022 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36297470
7.
BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib.
JTO Clin Res Rep
; 2(3): 100113, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34589994
8.
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.
Nat Commun
; 12(1): 7008, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34853302
9.
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
Lung Cancer
; 150: 62-69, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33070053
10.
Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study.
JAMA Oncol
; 6(7): 1063-1067, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32271353
11.
BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale.
Cancers (Basel)
; 11(9)2019 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31533235
12.
Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 20(3): 167-177, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30885551
13.
Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC).
EBioMedicine
; 39: 207-214, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30473379
14.
Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.
J Thorac Oncol
; 14(2): 304-310, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30472259
15.
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.
Ther Adv Med Oncol
; 10: 1758834017749748, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29383037
16.
Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.
Melanoma Res
; 28(3): 195-203, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29481492
17.
Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
EBioMedicine
; 29: 112-127, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29433983
18.
Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Sci Rep
; 13(1): 3620, 2023 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36869103
19.
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.
Nat Commun
; 8(1): 410, 2017 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28871105
20.
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
J Natl Cancer Inst
; 109(9)2017 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28376152